Ardelyx Inc
NASDAQ:ARDX

Watchlist Manager
Ardelyx Inc Logo
Ardelyx Inc
NASDAQ:ARDX
Watchlist
Price: 6.2 USD 5.08% Market Closed
Market Cap: 1.5B USD

Gross Margin
Ardelyx Inc

88.2%
Current
87%
Average
63.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
88.2%
=
Gross Profit
351.3m
/
Revenue
398.2m

Gross Margin Across Competitors

No Stocks Found

Ardelyx Inc
Glance View

Market Cap
1.5B USD
Industry
Biotechnology

Ardelyx Inc. is a biopharmaceutical company that operates at the nexus of innovative drug development, focusing primarily on pioneering treatments for cardiorenal and gastrointestinal diseases. Founded in 2007, Ardelyx has carved a niche for itself by targeting novel therapeutics to address unmet medical needs. The company's flagship product, tenapanor, exemplifies its core strategy. Tenapanor is designed to treat hyperphosphatemia in patients with chronic kidney disease on dialysis by inhibiting the NHE3 sodium transporter in the gut. This mechanism not only addresses phosphate levels but also showcases Ardelyx's approach of modifying pathways at their source to provide significant clinical benefits. The company navigates a complex landscape fraught with regulatory challenges, but its focused pipeline and ability to secure FDA approval for its products underscore its commitment to improving patient outcomes. Ardelyx generates revenue through the commercialization of its products, partnerships, and licensing agreements. The company primarily monetizes tenapanor, its leading therapeutic, which has gained traction in both U.S. and international markets. While the initial stages of bringing a drug to market involve substantial investment in research and development, regulatory approvals, and marketing, Ardelyx's strategic collaborations further augment its revenue streams. These partnerships, often with larger pharmaceutical entities, provide avenues for both upfront payments and milestone achievements as conditions are met. This multifaceted approach not only sustains the company financially but also enhances its capacity to innovate and expand its therapeutic horizons in the biopharmaceutical industry.

ARDX Intrinsic Value
12.41 USD
Undervaluation 50%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
88.2%
=
Gross Profit
351.3m
/
Revenue
398.2m
What is the Gross Margin of Ardelyx Inc?

Based on Ardelyx Inc's most recent financial statements, the company has Gross Margin of 88.2%.

Back to Top